Subscribe To
KYKOF / Kyowa Kirin: High-Risk High-Return Call Reiterating Our Buy Rating
KYKOF News
By Reuters
October 5, 2023
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln
Japanese pharmaceutical firm Kyowa Kirin said on Thursday it would acquire Britain-based biopharmaceutical company Orchard Therapeutics for $477.6 mil more_horizontal
By Seeking Alpha
September 24, 2023
Kyowa Kirin: High-Risk High-Return Call Reiterating Our Buy Rating
Kyowa Kirin shares are viewed as a cheap option on the positive outcome for the atopic dermatitis drug being developed with Amgen. The company's recen more_horizontal